Surface Antigen Expression and Complement Susceptibility of Differentiated Neuroblastoma Clones

This publication has 19 references indexed in Scilit:

• Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age.
  Journal of Clinical Oncology, 1998
• 3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study.
  International Journal of Oncology, 1998
• Expression of rat CD59: functional analysis confirms lack of species selectivity and reveals that glycosylation is not required for function
  Immunology, 1997
• Mapping the Active Site of CD59
  The Journal of Experimental Medicine, 1997
• Cell lineage and differentiation state are primary determinants of MYCN gene expression and malignant potential in human neuroblastoma cells.
  1997
• Complement-mediated tumor cell damage induced by antibodies against membrane cofactor protein (MCP, CD46).
  The Journal of Experimental Medicine, 1990
• Quantitative analysis of membrane cofactor protein (MCP) of complement. High expression of MCP on human leukemia cell lines, which is down-regulated during cell differentiation.
  The Journal of Immunology, 1990
• CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells.
  The Journal of Experimental Medicine, 1989
• Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro.
  Journal of Clinical Investigation, 1988
• Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria.
  The Journal of Experimental Medicine, 1985